EU/3/09/708 - orphan designation for treatment of hyperphenylalaninaemia
pegylated recombinant phenylalanine ammonia lyase (pegvaliase)
Orphan
Human
Overview
This medicine is now known as pegvaliase.
On 28 January 2010, orphan designation (EU/3/09/708) was granted by the European Commission to BioMarin Europe Ltd, United Kingdom, for pegylated recombinant phenylalanine ammonia lyase for the treatment of hyperphenylalaninaemia.
The sponsorship was transferred to BioMarin International Limited, Ireland, in August 2016.
Pegylated recombinant phenylalanine ammonia lyase has been authorised in the EU as Palynziq since 3 May 2019.
Hyperphenylalaninaemia is high levels of phenylalanine in the blood. Phenylalanine is an amino acid, one of the building blocks of proteins, and comes from the diet. Hyperphenylalaninaemia mainly occurs in patients with a genetic disorder called phenylketonuria (PKU). Patients with this disorder cannot convert phenylalanine into tyrosine (another amino acid). This causes a build-up of phenylalanine in the blood, which causes problems with the brain and nervous system.
Hyperphenylalaninaemia is a long-term debilitating disease that leads to mental retardation if left untreated.
At the time of designation, hyperphenylalaninaemia affected approximately 1.7 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 86,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 504,800,000 (Eurostat 2009).
At the time of designation, one product was authorised in the EU for the treatment of hyperphenylalaninaemia. In addition, patients were advised to follow a lifelong strict diet low in phenylalanine-containing foods (such as meat, fish, eggs, nuts, legumes and corn) to reduce phenylalanine intake.
The sponsor has provided sufficient information to show that pegylated recombinant phenylalanine ammonia lyase might be of significant benefit for patients with hyperphenylalaninaemia because it works in a different way to existing treatment and because early studies indicate that it might improve the outcome of patients who do not respond to existing treatment. These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
Hyperphenylalaninaemia is mainly caused by the lack of phenylalanine hydroxylase (PAH), an enzyme that converts phenylalanine into tyrosine.
Pegylated recombinant phenylalanine ammonia lyase is a bacterial enzyme that can break down phenylalanine in a similar way to PAH. In the body, it is expected to replace the missing PAH. This is expected to stop the accumulation of phenylalanine in the body, relieving the symptoms of the disease.
Pegylated recombinant phenylalanine ammonia lyase is made by a method known as 'recombinant DNA technology': it is made by a bacterium that has received a gene (DNA) that makes it able to produce phenylalanine ammonia lyase. The enzyme has also been modified by a process called 'pegylation', meaning that it has been attached to a chemical called polyethylene glycol.
The effects of pegylated recombinant phenylalanine ammonia lyase have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials in patients with hyperphenylalaninaemia were ongoing.
At the time of submission, pegylated recombinant phenylalanine ammonia lyase was not authorised anywhere in the EU for hyperphenylalaninaemia or designated as an orphan medicinal product elsewhere for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 5 November 2009recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- pegylated recombinant phenylalanine ammonia lyase (pegvaliase)
- Intended use
- Treatment of hyperphenylalaninaemia
- Orphan designation status
- Positive
- EU designation number
- EU/3/09/708
- Date of designation
- Sponsor
BioMarin International Limited
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Palynziq at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the orphan medicine assessment report Palynziq : Orphan maintenance assessment report (initial authorisation).
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: